向IL-17A增强了在费城染色体阳性B细胞急性淋巴细胞白血病中imatinib的疗效
Feng Wang1,2, Yunxuan Li2, Zhaona Yang1,3,4
1State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, 100050, Beijing, China.
Nature communications
|January 3, 2024
概括
在费城染色体阳性B型急性淋巴细胞白血病 (Ph+ B-ALL) 中,T辅助型17 (Th17) 细胞和IL-17A升高,促进白血病的进展和耐药性. 准这些免疫细胞可能为Ph + B-ALL提供新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 在瘤学瘤学.
背景情况:
- 白血病细胞破坏了造血,造成免疫失衡,导致白血病发生和药物耐药性.
- 准免疫位是一个潜在的策略,以克服疾病进展和耐氨酸激酶抑制剂 (TKI) 耐药性在费城染色体阳性B型急性淋巴细胞白血病 (Ph+ B-ALL).
研究的目的:
- 研究T辅助型17 (Th17) 细胞和IL-17A在Ph+B-ALL的进展中的作用.
- 阐明Th17细胞和IL-17A对Ph+ B-ALL的白血病发生和药物耐药性有所贡献的机制.
主要方法:
- 在Ph+ B-ALL患者中分析Th17细胞和IL-17A水平.
- 研究IL-17A对Ph+ B-ALL细胞信号通路 (BCR-ABL,IL6/JAK/STAT3,NF-kB) 的影响.
- 检查IL-17A诱导的CXCL16分泌在Th17细胞分化和招募中的作用.
主要成果:
- 在Ph+ B-ALL患者中,Th17细胞和IL-17A表达显著升高.
- IL-17A通过激活关键信号通路,增强细胞增殖和存活,直接促进Ph + B-ALL的进展.
- 刺激IL-17A的白血病细胞分泌CXCL16,促进一个积极的反循环,促进Th17分化并吸引Th17细胞,从而支持白血病的进展.
结论:
- Th17细胞和IL-17A在Ph+B-ALL的进展中起着至关重要的作用.
- 已识别的IL-17A-CXCL16-Th17轴代表了一种驱动白血病进展的新机制.
- 准Th17丰富的免疫位为Ph + B-ALL治疗提供了一个有前途的治疗途径.
更多相关视频
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529


